S. Hennessy

First name
Last name
Flory, J. H., Ellenberg, S., Szapary, P. O., Strom, B. L., & Hennessy, S. (2009). Antidiabetic action of bezafibrate in a large observational database. Diabetes Care. http://doi.org/10.2337/dc08-1809
Re, 3rd. L., Haynes, K., Ming, E. E., Ives, W., Horne, L. N., Fortier, K., et al. (2012). Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3318
Leonard, C. E., Freeman, C. P., Newcomb, C. W., Reese, P. P., Herlim, M., Bilker, W. B., et al. (2012). Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3329
Carbonari, D. M., Saine, M. E., Newcomb, C. W., Blak, B., Roy, J. A., Haynes, K., et al. (2015). Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3844
Saine, M. E., Carbonari, D. M., Newcomb, C. W., Nezamzadeh, M. S., Haynes, K., Roy, J. A., et al. (2015). Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol. http://doi.org/10.1186/s40360-015-0007-z
Re, L., Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., et al. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400
Saine, M. E., Carbonari, D. M., Newcomb, C. W., Gallagher, A. M., Blak, B. T., Roy, J. A., et al. (2019). Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4853